Print Version |
Net sales during the three months ended
CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 71.5% to
Based on our current sales order volumes and forecasts we have received from our customers, we now anticipate our fiscal 2023 consolidated net sales will be slightly up as compared to fiscal 2022. While sales are expected to increase during fiscal 2023 when compared to fiscal 2022, we anticipate operating income will be negatively impacted by changes in sales mix, unfavorable foreign exchange rates, and inflationary factors including increased operational costs impacted by increased labor, raw material, freight and supply chain costs. We are working with both suppliers and customers to attempt to mitigate the expected negative impact on our fiscal 2023 financial results. There can be no assurances our expectations will result in the currently anticipated increase in net sales and expected operating income levels.
As of
"Much like many other industries, we believe the dietary supplement industry has entered a period of constrained growth due to the effect inflation is having on consumer behaviors. This inflationary impact appears to have affected the Sports Nutrition Industry most significantly, but there are indications that other areas of the dietary supplement industry are experiencing the same economic pressures. We believe we have a strong core business and this foundation coupled with the strength of our balance sheet will help us weather this economic storm."
"Construction on our new powder manufacturing facility in
"We remain committed to delivering value for our shareholders as we repurchased 46,795 shares of our common stock in the first quarter of fiscal 2023 and intend to continue to opportunistically buy back shares in the future. While we see macro challenges across the economy ahead, our team is working hard across all departments to navigate these obstacles, deliver superior service for our customers and drive sales growth and profitability."
An updated investor presentation will be posted to the investor relations page on our website later today (https://www.nai-online.com/our-company/investors/).
NAI, headquartered in
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our ability to develop, maintain or increase sales to new and existing customers, our ability to attract and retain sufficient labor, COVID-19 and related impacts on the availability of raw materials, our future revenue profits and financial condition, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks, including those set forth from time to time in the documents filed by us with the
CONTACT –
Web site: http://www.nai-online.com
|
|||||||
CONDENSED CONSOLIDATED STATEMENTS OF INCOME |
|||||||
(In thousands, except per share data) |
|||||||
(Unaudited) |
|||||||
Three Months Ended |
|||||||
|
|||||||
2022 |
2021 |
||||||
|
|
100.0 % |
|
100.0 % |
|||
Cost of goods sold |
37,756 |
87.5 % |
30,059 |
78.4 % |
|||
Gross profit |
5,371 |
12.5 % |
8,281 |
21.6 % |
|||
Selling, general & administrative expenses |
3,829 |
8.9 % |
4,053 |
10.6 % |
|||
INCOME FROM OPERATIONS |
1,542 |
3.6 % |
4,228 |
11.0 % |
|||
Other loss, net |
(224) |
-0.5 % |
(26) |
-0.1 % |
|||
INCOME BEFORE TAXES |
1,318 |
3.1 % |
4,202 |
11.0 % |
|||
Income tax expense |
265 |
946 |
|||||
NET INCOME |
$ 1,053 |
$ 3,256 |
|||||
NET INCOME PER COMMON SHARE: |
|||||||
Basic: |
|
|
|||||
Diluted: |
|
|
|||||
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: |
|||||||
Basic |
5,920 |
6,288 |
|||||
Diluted |
5,943 |
6,351 |
|
|||
CONDENSED CONSOLIDATED BALANCE SHEETS |
|||
(In thousands) |
|||
|
|
||
2022 |
2022 |
||
(Unaudited) |
|||
ASSETS |
|||
Cash and cash equivalents |
|
|
|
Accounts receivable, net |
14,822 |
17,422 |
|
Inventories, net |
39,990 |
32,475 |
|
Other current assets |
7,251 |
5,016 |
|
Total current assets |
74,404 |
76,746 |
|
Property and equipment, net |
51,384 |
44,573 |
|
Operating lease right-of-use assets |
21,136 |
21,701 |
|
Other noncurrent assets, net |
2,644 |
2,983 |
|
Total Assets |
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|||
Accounts payable and accrued liabilities |
25,441 |
25,641 |
|
Line of Credit |
3,400 |
- |
|
Mortgage note payable |
9,727 |
9,795 |
|
Long-term liability - operating leases |
21,144 |
22,047 |
|
Total Liabilities |
59,712 |
57,483 |
|
Stockholders' Equity |
89,856 |
88,520 |
|
Total Liabilities and Stockholders' Equity |
|
|
View original content:https://www.prnewswire.com/news-releases/natural-alternatives-international-inc-announces-2023-q1-results-301673666.html
SOURCE